These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17224882)

  • 1. Platelet protagonist/antagonist: understanding the distinguishing characteristics of anticoagulants.
    Schneider DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 3():S3-11. PubMed ID: 17224882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
    Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
    Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin, thrombin and platelets: clinical implications and future directions.
    Becker R; Butenas S; Carr M; Jaffer F; Kleiman NS; Marmur JD; Schneider DJ; Spiess BD; Steinhubl SR; Weitz JI
    J Invasive Cardiol; 2003 Aug; Suppl():2-15. PubMed ID: 23570139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of bivalirudin on tissue factor-triggered coagulation.
    Butenas S; Orfeo T; Brummel-Ziedins KE; Mann KG
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):407-14. PubMed ID: 17581314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.
    Hoffman M; Monroe DM; Oliver JA; Roberts HR
    Blood; 1995 Sep; 86(5):1794-801. PubMed ID: 7655009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.
    Schneider DJ; Keating F; Sobel BE
    Coron Artery Dis; 2006 Aug; 17(5):471-6. PubMed ID: 16845256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet procoagulant complex assembly in a tissue factor-initiated system.
    Monroe DM; Roberts HR; Hoffman M
    Br J Haematol; 1994 Oct; 88(2):364-71. PubMed ID: 7803283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Insights Into the Regulation of Coagulation and Thrombosis.
    Li X; Sim MMS; Wood JP
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):e119-e125. PubMed ID: 32320291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
    Lindhout T; Blezer R; Hemker HC
    Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
    Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
    Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.
    Lev EI; Patel R; Karim A; Kleiman A; Badimon JJ; Kleiman NS
    Thromb Haemost; 2006 Mar; 95(3):441-6. PubMed ID: 16525571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.
    Wilson SJ; Connolly TM; Peters G; Ghosh A; Johnson M; Newby DE
    Cardiovasc Res; 2019 Mar; 115(3):669-677. PubMed ID: 30184110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targets for antithrombotic drugs.
    Thiagarajan P
    Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
    Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
    Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.
    Pujadas-Mestres L; Lopez-Vilchez I; Arellano-Rodrigo E; Reverter JC; Lopez-Farre A; Diaz-Ricart M; Badimon JJ; Escolar G
    PLoS One; 2017; 12(2):e0171486. PubMed ID: 28192448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin.
    Warkentin TE; Greinacher A; Koster A
    Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin: an anticoagulant option for percutaneous coronary intervention.
    Bates ER
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):153-62. PubMed ID: 15151464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia: a general review.
    Swanson JM
    J Infus Nurs; 2007; 30(4):232-40. PubMed ID: 17667079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.